Viewing Study NCT00621361

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:55 AM
Ignite Modification Date: 2026-01-11 @ 10:18 AM
Study NCT ID: NCT00621361
Status: COMPLETED
Last Update Posted: 2012-12-17
First Post: 2008-02-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lung Cancer View
None AZD2171 View
None cediranib View
None RECENTIN View
None etoposide View
None cisplatin View